World Journal of Gastroenterology · 2020 · 25 citations · 34 references
MedicineBiochemistryPharmacologyBiochemical PharmacologyDiabetologyMolecular PharmacologyDiabetes MellitusDiabetes Mellitus BiochemistryDiabetes PharmacotherapyDiabetic RetinopathySodium-glucose Cotransporter 2 InhibitorsTransporter PharmacologyAntidiabetic Drug TherapyGut Microbiome AlterationsGut Microbiome DysbiosisMicrovascular ComplicationsRenal Glucose ReabsorptionSodium-glucose CotransportSodium-glucose Cotransporter 2 InhibitionSuccinate Metabolism
BACKGROUND: alterations of the gut microbiome and tested this in a type 1 diabetic mouse model of diabetic retinopathy. AIM: To determine whether the treatment with two independent SGLT2 inhibitors affects gut health in a type 1 diabetic mouse model. METHODS: their drinking water. Serum samples were collected and the concentration of succinate and the short chain fatty acid (SCFA) butyric acid was measured using gas chromatography-mass spectrometry. Enzyme-linked immunosorbent assay (ELISA) was performed to determine the concentration of insulin and leptin. Furthermore, the norepinephrine content in kidney tissue was determined using ELISA. Pancreatic tissue was collected and stained with haematoxylin and eosin and analysed using brightfield microscopy. RESULTS: Due to the presence of the Akita allele, both Akita and Akimba mice showed a reduction in insulin production compared to C57BL/6J and Kimba mice. Furthermore, Akita mice also showed the presence of apoptotic bodies within the pancreatic islets. The acinar cells of Akita and Akimba mice showed swelling which is indicative of acute injury or pancreatitis. After 8 wk of SGLT2 inhibition with dapagliflozin, the intermediate metabolite of gut metabolism known as succinate was significantly reduced in Akimba mice when compared to DMSO treated mice. In addition, empagliflozin resulted in suppression of succinate levels in Akimba mice. The beneficial SCFA known as butyric acid was significantly increased in Akita mice after treatment with dapagliflozin when compared to vehicle treated mice. The norepinephrine content in the kidney was significantly reduced with both dapagliflozin and empagliflozin therapy in Akita mice and was significantly reduced in Akimba mice treated with empagliflozin. In non-diabetic C57BL/6J and Kimba mice, serum leptin levels were significantly reduced after dapagliflozin therapy. CONCLUSION: The inhibition of SGLT2 reduces the intermediate metabolite succinate, increases SCFA butyric acid levels and reduces norepinephrine content in mouse models of T1D. Collectively, these improvements may represent an important mechanism underlying the potential benefits of SGLT2 inhibition in T1D and its complications.
34
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Enterotypes of the human gut microbiome
Manimozhiyan Arumugam, Jeroen Raes, Éric Pelletier et al. · Nature · 2011 · 7.6K citations · Full text
A metagenome-wide association study of gut microbiota in type 2 diabetes
Junjie Qin, Yingrui Li, Zhiming Cai et al. · Nature · 2012 · 7K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text